Literature DB >> 17438336

Tumor necrosis factor-alpha stimulates focal adhesion kinase activity required for mitogen-activated kinase-associated interleukin 6 expression.

David D Schlaepfer1, Shihe Hou, Ssang-Taek Lim, Alok Tomar, Honggang Yu, Yangmi Lim, Dan A Hanson, Sean A Uryu, John Molina, Satyajit K Mitra.   

Abstract

Focal adhesion kinase (FAK) is a cytoplasmic protein-tyrosine kinase that promotes cell migration, survival, and gene expression. Here we show that FAK signaling is important for tumor necrosis factor-alpha (TNFalpha)-induced interleukin 6 (IL-6) mRNA and protein expression in breast (4T1), lung (A549), prostate (PC-3), and neural (NB-8) tumor cells by FAK short hairpin RNA knockdown and by comparisons of FAK-null (FAK(-/-)) and FAK(+/+) mouse embryo fibroblasts. FAK promoted TNFalpha-stimulated MAPK activation needed for maximal IL-6 production. FAK was not required for TNFalpha-mediated nuclear factor-kappaB or c-Jun N-terminal kinase activation. TNFalpha-stimulated FAK catalytic activation and IL-6 production were inhibited by FAK N-terminal but not FAK C-terminal domain overexpression. Analysis of FAK(-/-) fibroblasts stably reconstituted with wild type or various FAK point mutants showed that FAK catalytic activity, Tyr-397 phosphorylation, and the Pro-712/713 proline-rich region of FAK were required for TNFalpha-stimulated MAPK activation and IL-6 production. Constitutively activated MAPK kinase-1 (MEK1) expression in FAK(-/-) and A549 FAK short hairpin RNA-expressing cells rescued TNFalpha-stimulated IL-6 production. Inhibition of Src protein-tyrosine kinase activity or mutation of Src phosphorylation sites on FAK (Tyr-861 or Tyr-925) did not affect TNFalpha-stimulated IL-6 expression. Moreover, analyses of Src(-/-), Yes(-/-), and Fyn(-/-) fibroblasts showed that Src expression was inhibitory to TNFalpha-stimulated IL-6 production. These studies provide evidence for a novel Src-independent FAK to MAPK signaling pathway regulating IL-6 expression with potential importance to inflammation and tumor progression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17438336     DOI: 10.1074/jbc.M610672200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  30 in total

1.  Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models.

Authors:  Colin Walsh; Isabelle Tanjoni; Sean Uryu; Alok Tomar; Ju-Ock Nam; Hong Luo; Angelica Phillips; Neela Patel; Cheni Kwok; Gerald McMahon; Dwayne G Stupack; David D Schlaepfer
Journal:  Cancer Biol Ther       Date:  2010-05-15       Impact factor: 4.742

2.  Inhibition of astrocyte FAK-JNK signaling promotes subventricular zone neurogenesis through CNTF.

Authors:  Cuihong Jia; Matthew P Keasey; Chiharu Lovins; Theo Hagg
Journal:  Glia       Date:  2018-11       Impact factor: 7.452

3.  Contribution of Fibroblast and Mast Cell (Afferent) and Tumor (Efferent) IL-6 Effects within the Tumor Microenvironment.

Authors:  Honor J Hugo; Stephanie Lebret; Eva Tomaskovic-Crook; Nuzhat Ahmed; Tony Blick; Donald F Newgreen; Erik W Thompson; M Leigh Ackland
Journal:  Cancer Microenviron       Date:  2012-02-08

4.  Oxidized LDL induces FAK-dependent RSK signaling to drive NF-κB activation and VCAM-1 expression.

Authors:  Arif Yurdagul; Florian J Sulzmaier; Xiao L Chen; Christopher B Pattillo; David D Schlaepfer; A Wayne Orr
Journal:  J Cell Sci       Date:  2016-02-18       Impact factor: 5.285

5.  Pyk2 inhibition of p53 as an adaptive and intrinsic mechanism facilitating cell proliferation and survival.

Authors:  Ssang-Taek Lim; Nichol L G Miller; Ju-Ock Nam; Xiao Lei Chen; Yangmi Lim; David D Schlaepfer
Journal:  J Biol Chem       Date:  2009-10-30       Impact factor: 5.157

6.  Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression.

Authors:  Kristy K Ward; Isabelle Tancioni; Christine Lawson; Nichol L G Miller; Christine Jean; Xiao Lei Chen; Sean Uryu; Josephine Kim; David Tarin; Dwayne G Stupack; Steven C Plaxe; David D Schlaepfer
Journal:  Clin Exp Metastasis       Date:  2012-12-30       Impact factor: 5.150

7.  Targeted focal adhesion kinase activation in cardiomyocytes protects the heart from ischemia/reperfusion injury.

Authors:  Zhaokang Cheng; Laura A DiMichele; Zeenat S Hakim; Mauricio Rojas; Christopher P Mack; Joan M Taylor
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-03-01       Impact factor: 8.311

8.  Blood vitronectin is a major activator of LIF and IL-6 in the brain through integrin-FAK and uPAR signaling.

Authors:  Matthew P Keasey; Cuihong Jia; Lylyan F Pimentel; Richard R Sante; Chiharu Lovins; Theo Hagg
Journal:  J Cell Sci       Date:  2018-02-02       Impact factor: 5.285

Review 9.  FERM control of FAK function: implications for cancer therapy.

Authors:  Ssang-Taek Lim; David Mikolon; Dwayne G Stupack; David D Schlaepfer
Journal:  Cell Cycle       Date:  2008-05-29       Impact factor: 4.534

10.  Phosphorylation of RACK1 on tyrosine 52 by c-Abl is required for insulin-like growth factor I-mediated regulation of focal adhesion kinase.

Authors:  Patrick A Kiely; George S Baillie; Robert Barrett; Deirdre A Buckley; David R Adams; Miles D Houslay; Rosemary O'Connor
Journal:  J Biol Chem       Date:  2009-05-07       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.